New study: can a simple powder keep kidney patients out of the ER?
NCT ID NCT05347693
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether continuing a drug called sodium zirconium cyclosilicate (Lokelma) after hospital discharge helps people with chronic kidney disease maintain normal potassium levels. 186 hospitalized patients were randomly assigned to either continue the drug or receive standard care. The goal was to see if the drug reduces potassium-related hospital visits and keeps potassium in a healthy range for 180 days after discharge.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sodium zirconium cyclosilicate (Lokelma)
What this could lead to
If it works, this could show that continuing this medication after leaving the hospital helps keep potassium levels normal and reduces the need for emergency care.
What could go wrong
This is a completed phase 4 study with 186 participants, so results are available but may not apply to all patients. The open-label design means both patients and doctors knew which treatment was given, which can bias results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Bonheiden, 2820, Belgium
-
Research Site
Leuven, 3000, Belgium
-
Research Site
Annonay, 07103, France
-
Research Site
Ars-Laquenexy, 57530, France
-
Research Site
Nice, 06000, France
-
Research Site
Saint-Priest-en-Jarez, 42270, France
-
Research Site
Bari, 70120, Italy
-
Research Site
Foggia, 71122, Italy
-
Research Site
Parma, 43125, Italy
-
Research Site
Pavia, 27100, Italy
-
Research Site
Eindhoven, 5602 ZA, Netherlands
-
Research Site
Algeciras, 11207, Spain
-
Research Site
Almería, 04009, Spain
-
Research Site
Badajoz, 06080, Spain
-
Research Site
Barcelona, 08907, Spain
-
Research Site
Burgos, 9006, Spain
-
Research Site
Getafe, 28905, Spain
-
Research Site
Madrid, 28007, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Salamanca, 37007, Spain
-
Research Site
San Sebastián de los Reyes, 28702, Spain
-
Research Site
Seville, 41009, Spain
-
Research Site
Talavera de la Reina, 45600, Spain
-
Research Site
Zamora, 49022, Spain
-
Research Site
Doncaster, DN2 5LT, United Kingdom
-
Research Site
Hull, HU10 7AZ, United Kingdom
-
Research Site
Salford, M6 8HD, United Kingdom
-
Research Site
Stevenage, SG1 4AB, United Kingdom